NASDAQ:PRLD

Prelude Therapeutics Q3 2026 Earnings Results & Report

Prelude Therapeutics logo
$3.41 -0.04 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$3.32 -0.09 (-2.58%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prelude Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.12 versus the $0.01 consensus estimate, while revenue of $5.65 million fell short of the $29 million estimate by $23.35 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Prelude Therapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
$0.01
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Prelude Therapeutics Revenue Results

Actual Revenue
$5.65 million
Expected Revenue
$29 million
Beat/Miss
Missed by -$23.35 million
YoY Revenue Growth
N/A

Prelude Therapeutics Q3 2026 Earnings FAQ

Prelude Therapeutics (NASDAQ:PRLD) reported earnings of -$0.12 per share for Q3 2026, missing the consensus estimate of $0.01. The report was announced on Monday, November 16, 2026.

Prelude Therapeutics reported revenue of $5.65 million for Q3 2026, against a consensus estimate of $29 million.

Prelude Therapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Prelude Therapeutics (PRLD) Expected to Release Earnings on Wednesday
See More Prelude Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email.

About Prelude Therapeutics

Prelude Therapeutics (NASDAQ:PRLD) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival.

Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

Founded in 2016 and based in Wilmington, Delaware, Prelude conducts its drug discovery and development work in the United States. Its programs are intended to address unmet needs in oncology through targeted approaches.

View Prelude Therapeutics Profile